Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review

Phase III study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup.

(2020) Masatoshi Kudo et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.

(2020) Aiwu Ruth He et al.   JOURNAL OF CLINICAL ONCOLOGY

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

(2020) Shukui Qin et al.   LANCET ONCOLOGY

Frequency and Implications of myeloid-derived suppressor cells and lymphocyte subsets in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma

(2019) Helal F. Hetta et al.   JOURNAL OF MEDICAL VIROLOGY

Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC).

(2019) Charalampos S. Floudas et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy

(2019) Anthony Tanoto Tan et al.   GASTROENTEROLOGY

O-027Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240

(2019) R S Finn et al.   ANNALS OF ONCOLOGY

Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study

(2019) Edward Gane et al.   JOURNAL OF HEPATOLOGY

Tumor-Infiltrating Leukocyte Composition and Prognostic Power in Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas

(2019) Yi-Wen Hsiao et al.   Genes

HBV-Induced Immune Imbalance in the Development of HCC

(2019) Yongyan Chen et al.   Frontiers in Immunology

LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

(2019) T Yau et al.   ANNALS OF ONCOLOGY

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

(2019) Xuanye Zhang et al.   Journal for ImmunoTherapy of Cancer

Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma

(2018) Chun Jye Lim et al.   GUT

The role of IDO, IL-10 and TGF-β in the HCV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma

(2018) Ruonan Yang et al.   JOURNAL OF MEDICAL VIROLOGY

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection

(2018) Scott Balsitis et al.   PLoS One

Immunotherapy for Head and Neck Squamous Cell Carcinoma

(2018) Jessica Moskovitz et al.   Current Oncology Reports

Expression and significance of peripheral myeloid-derived suppressor cells in chronic hepatitis B patients

(2018) Y. Lv et al.   Clinics and Research in Hepatology and Gastroenterology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma

(2018) Xue Han et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).

(2018) Masafumi Ikeda et al.   JOURNAL OF CLINICAL ONCOLOGY

1151PCemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study

(2018) M J Pishvaian et al.   ANNALS OF ONCOLOGY

699PReal-world data on nivolumab treatment in Asian patients with advanced hepatocellular carcinoma

(2018) S E Yoon et al.   ANNALS OF ONCOLOGY

Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

(2018) Jianming Xu et al.   CLINICAL CANCER RESEARCH

Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers

(2018) Fabian Finkelmeier et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis

(2018) Jixiang Liu et al.   OncoTargets and Therapy

Genomic and transcriptional Profiling of tumor infiltrated CD8+ T cells revealed functional heterogeneity of antitumor immunity in hepatocellular carcinoma

(2018) Zhenli Li et al.   OncoImmunology

Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection

(2017) Janine Kah et al.   JOURNAL OF CLINICAL INVESTIGATION

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Safety and Tolerability of PD‐1/PD‐L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta‐Analysis

(2017) Tomohiro F. Nishijima et al.   ONCOLOGIST

Immune Regulation by T Regulatory Cells in Hepatitis B Virus-Related Inflammation and Cancer

(2017) N. Trehanpati et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma

(2017) Xiaomeng Dai et al.   Translational Oncology

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis

(2016) Fabian Finkelmeier et al.   EUROPEAN JOURNAL OF CANCER

Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region

(2016) Ran Xu Zhu et al.   Gut and Liver

Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma

(2016) Tai Hato et al.   Immunotherapy

Mechanisms of HBV-induced hepatocellular carcinoma

(2016) Massimo Levrero et al.   JOURNAL OF HEPATOLOGY

Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma

(2016) Zhu Li et al.   MEDICINE

PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas

(2016) Aaron Goodman et al.   Nature Reviews Clinical Oncology

The clinical and prognostic significance of CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy

(2016) Dong Wang et al.   TUMOR BIOLOGY

Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients

(2016) Xian-Shu Gao et al.   OncoTargets and Therapy

High-throughput T cell receptor sequencing reveals distinct repertoires between tumor and adjacent non-tumor tissues in HBV-associated HCC

(2016) Yunqing Chen et al.   OncoImmunology

Significant Roles of Regulatory T Cells and Myeloid Derived Suppressor Cells in Hepatitis B Virus Persistent Infection and Hepatitis B Virus-Related HCCs

(2015) Yasuteru Kondo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The yin and yang of evasion and immune activation in HCC

(2015) Oxana V. Makarova-Rusher et al.   JOURNAL OF HEPATOLOGY

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013

(2015) Aparna Schweitzer et al.   LANCET

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

(2015) Kim C. Ohaegbulam et al.   TRENDS IN MOLECULAR MEDICINE

Molecular biology of hepatitis B virus infection

(2015) Christoph Seeger et al.   VIROLOGY

CD4+CD25+CD127low Regulatory T Cells Play Predominant Anti-Tumor Suppressive Role in Hepatitis B Virus-Associated Hepatocellular Carcinoma

(2015) Shreya Sharma et al.   Frontiers in Immunology

Effects of entecavir on peripheral blood lymphocyte profiles in chronic hepatitis B patients with suboptimal responses to adefovir

(2014) Liwen Zhang et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

PD-1 mRNA expression is associated with clinical and viral profile and PD1 3′-untranslated region polymorphism in patients with chronic HBV infection

(2014) Guoyu Zhang et al.   IMMUNOLOGY LETTERS

Efficient generation of highly immunocompetent dendritic cells from peripheral blood of patients with hepatitis C virus-related hepatocellular carcinoma

(2014) Masaaki Kitahara et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

TGF-β-dependent induction of CD4+CD25+Foxp3+ Tregs by liver sinusoidal endothelial cells

(2014) Antonella Carambia et al.   JOURNAL OF HEPATOLOGY

Myeloid-Derived Suppressor Cells Regulate Immune Response in Patients with Chronic Hepatitis B Virus Infection through PD-1–Induced IL-10

(2014) Ang Huang et al.   JOURNAL OF IMMUNOLOGY

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Pathogen-Driven Cancers and Emerging Immune Therapeutic Strategies

(2014) N. Vandeven et al.   Cancer Immunology Research

T-Cells from HLA-B*57:01+ Human Subjects Are Activated with Abacavir through Two Independent Pathways and Induce Cell Death by Multiple Mechanisms

(2013) Catherine C. Bell et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Ipilimumab associated hepatitis: imaging and clinicopathologic findings

(2013) Kyung Won Kim et al.   INVESTIGATIONAL NEW DRUGS

Update on epidemiology of hepatitis B and C in China

(2013) Yan Cui et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Augmentation of Hepatitis B Virus-Specific Cellular Immunity with Programmed Death Receptor-1/Programmed Death Receptor-L1 Blockade in Hepatitis B Virus and HIV/Hepatitis B Virus Coinfected Patients Treated with Adefovir

(2012) Amy C. Sherman et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis B

(2012) Patrick T.F. Kennedy et al.   GASTROENTEROLOGY

Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma

(2012) Hashem B. El-Serag   GASTROENTEROLOGY

Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma

(2012) Hang Li et al.   HEPATOLOGY

Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+ T cell in HCC patients

(2012) Fu-Jun Li et al.   IMMUNOLOGY LETTERS

PD-1 Blockage Reverses Immune Dysfunction and Hepatitis B Viral Persistence in a Mouse Animal Model

(2012) Horng-Tay Tzeng et al.   PLoS One

Altered cytokine levels and increased CD4+CD57+ T cells in the peripheral blood of hepatitis C virus-related hepatocellular carcinoma patients

(2011) Eiji Takayama   ONCOLOGY REPORTS

Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma

(2011) Zhen Zeng et al.   PLoS One

Expansion of CD4+CD25+FoxP3+regulatory T cells in hepatitis C virus-related chronic hepatitis, cirrhosis and hepatocellular carcinoma

(2010) Kai Yoshizawa et al.   HEPATOLOGY RESEARCH

PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients

(2010) Feng Shi et al.   INTERNATIONAL JOURNAL OF CANCER

Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses

(2010) H. H. Zhang et al.   JOURNAL OF VIRAL HEPATITIS

Increased PD-1 and decreased CD28 expression in chronic hepatitis B patients with advanced hepatocellular carcinoma

(2010) Ping-Ning Hsu et al.   LIVER INTERNATIONAL

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

(2009) Q. Gao et al.   CLINICAL CANCER RESEARCH

Profile of Tumor Antigen-Specific CD8 T Cells in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma

(2009) Adam J. Gehring et al.   GASTROENTEROLOGY

Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B

(2009) Paola Fisicaro et al.   GASTROENTEROLOGY

Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor

(2009) Bastian Hoechst et al.   HEPATOLOGY

Immune tolerance: What is unique about the liver

(2009) Gisa Tiegs et al.   JOURNAL OF AUTOIMMUNITY

Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade

(2009) Nobuhiro Nakamoto et al.   PLoS Pathogens

Dynamic Programmed Death 1 Expression by Virus-Specific CD8 T Cells Correlates With the Outcome of Acute Hepatitis B

(2008) Zheng Zhang et al.   GASTROENTEROLOGY

A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells

(2008) Bastian Hoechst et al.   GASTROENTEROLOGY